“We look forward to a catalyst rich period with six clinical data updates guided from now to year-end across three clinical stage programs, including two oral presentations that have been accepted at major medical conferences and our targeted top-line randomized median PFS results for the darovasertib and crizotinib combination in 1L HLA-A2 negative MUM to potentially enable our first accelerated approval filing in the U.S. We are also excited to host our 10-year Anniversary R&D Day in New York City on September 8th, where we will present multiple data updates across our potential first-in-class clinical pipeline and highlight our strategic vision and pioneering research in cancer biology and drug discovery,” said Yujiro Hata, president and CEO, Ideaya Biosciences (IDYA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study
- JPMorgan ups Ideaya target, adds to Analyst Focus List
- IDEAYA Biosciences’ Promising Potential with IDE849: Analyst Charles Zhu’s Buy Rating Ahead of WCLC 2025
- Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025
- Ideaya Biosciences initiated with a Buy at TD Cowen